Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 63.08 CNY 0.99% Market Closed
Market Cap: 402.4B CNY

Jiangsu Hengrui Pharmaceuticals Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jiangsu Hengrui Pharmaceuticals Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
ÂĄ31B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
13%
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Revenue
ÂĄ26.2B
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
11%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
ÂĄ13.2B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
ÂĄ9.8B
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
ÂĄ40.8B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
ÂĄ5.8B
CAGR 3-Years
94%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.

Intrinsic Value
48.12 CNY
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Revenue?
Revenue
31B CNY

Based on the financial report for Sep 30, 2025, Jiangsu Hengrui Pharmaceuticals Co Ltd's Revenue amounts to 31B CNY.

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
13%

Over the last year, the Revenue growth was 19%. The average annual Revenue growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been 13% over the past three years , 4% over the past five years , and 13% over the past ten years .

Back to Top